Finally, IWP-2 treatment could also attenuate the expressions of markers of EMT (enhanced E-cadherin and reduced vimentin levels) and cancer stemness (reduced CD44 and Oct4a but increased CD24 levels) as seen in the castration-relapse VCaP-NURR1 tumors. The gene discussed is CD44; the disease is cancer.